

10 YEARS OF
BREAKTHROUGHS
A HEALTHIER
FUTURE



RESCEU
REspiratory Syncytial virus
Consortium in Europe

69

Prospective data collection on burden of RSV infection in Europe – paving the way for RSV vaccines and therapeutics

J.G. Wildenbeest, on behalf of RESCEU WP4

Facts & Figures


Start date:	01/01/2017
End date:	31/12/2017
Contributions	
IMI funding:	14,498,125 €
EFPIA in kind:	14 673 665 €
Total Cost :	29 171 790 €
Project website:	www.resc-eu.org
Social media:	twitter@RESCEUproject

Challenge

Respiratory Syncytial Virus (RSV) infection causes severe disease in young infants, older adults and COPD patients. Expectations are that a vaccine will be available in the near future. There is a substantial gap in knowledge on RSV morbidity and associated healthcare and social costs across Europe.

Aim: To provide better insights into the impact of RSV on individuals, health systems and societies throughout Europe, and to actively engage stakeholders in order to improve strategic planning and decision-making.


Approach & Methodology



Results


Birth Cohort study

10,000 healthy infants (1,000 active; 9,000 passive)




Older adult cohort study

1,000 adults ≥ 60 years of age



COPD cohort study

500 COPD patients



Value of IMI collaboration

- Active involvement of academia, EFPIA, public health institutions and patient organisations in the design and implementation of these studies.
- Active engagement of patient organisations from designing the study onwards.

Impact & take home message

RESCEU will provide **unique burden of disease estimates of RSV disease in Europe** which will help stakeholders and governments in Europe in decision making about **implementation of RSV vaccines and therapeutics** in the near future.



innovative
medicines
initiative



This work has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (RESCEU grant no 116019).